W R Ballou
Affiliation: MedImmune Vaccines
- Malaria vaccines: triumphs or tribulations?W R Ballou
Department of Immunology, Walter Reed Army Institute of Research, Washington, DC 20307 5100, USA
Parassitologia 41:403-8. 1999..It describes recent encouraging results in human subjects with the RTS,S vaccine, a promising pre-erythrocytic malaria vaccine candidate...
- Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1W Ripley Ballou
Clinical Development, MedImmune, Gaithersburg, Maryland 20878, USA
J Infect Dis 187:675-8. 2003..5 or 25 microg MEDI-491 at 0, 1, and 6 months. MEDI-491 was safe and immunogenic. All volunteers developed neutralizing antibody titers that peaked after the third immunization and were sustained through study day 364...
- Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccineJ A Stoute
Department of Immunology, Walter Reed Army Institute of Research, Washington, DC, USA
J Infect Dis 178:1139-44. 1998..2 days for the vaccinees (P < .01). Immune responses did not correlate with protection. Further optimization in vaccine composition and/or immunization schedule will be required to induce longer-lasting protective immunity...
- Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malariaC F Ockenhouse
Department of Immunology, Walter Reed Army Institute of Research, Washington, DC 20307, USA
J Infect Dis 177:1664-73. 1998....
- Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malariaK E Kester
Dept of Immunology, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910, USA
J Infect Dis 183:640-7. 2001..Overall protective efficacy of RTS,S/SBAS2 was 41% (95% confidence interval, 22%-56%; P=.0006). This and previous studies have shown that 2 or 3 doses of RTS,S/SBAS2 protect against challenge with P. falciparum sporozoites...
- Malaria rapid diagnostic devices: performance characteristics of the ParaSight F device determined in a multisite field studyJ R Forney
Walter Reed Army Institute of Research, Washington, D C, USA
J Clin Microbiol 39:2884-90. 2001..of asexual parasites per microliter of whole blood), sensitivities were 83% (>0 to 500 parasites/microl), 87% (501 to 1,000/microl), 98% (1,001 to 5,000/microl), and 98% (>5,000/microl). Device specificity was 86%...
- Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alumSathit Pichyangkul
Department of Immunology and Medicine, Armed Forces Research Institute of Medical Science AFRIMS, Bangkok, Thailand
Vaccine 22:3831-40. 2004..The notable difference in Th1/Th2 polarization induced by the AS02A and AS01B formulations warrants comparative clinical testing...
- Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western KenyaJose A Stoute
U S Army Medical Research Unit, Nairobi, Kenya
Am J Trop Med Hyg 75:166-70. 2006..We conclude that in this small study, RTS,S/AS02A is safe and similarly immunogenic in malaria-exposed African adults of different ethnicity in different transmission settings...
- Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of ResearchMark E Polhemus
Walter Reed Army Institute of Research, Silver Spring, MD, United States
Vaccine 25:4203-12. 2007..1/AS02A in an endemic population in the Republic of Mali...
- Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trialJohn J Aponte
Barcelona Centre for International Health Research CRESIB, Hospital Clinic Institut d Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
Lancet 370:1543-51. 2007..We aimed to assess the safety, immunogenicity, and initial efficacy of the malaria vaccine RTS,S/AS02D in infants in Africa...
- Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trialJahit Sacarlal
Centro de Investigação em Saúde de Manhiça, Manhiça, Mozambique
Vaccine 26:174-84. 2008..Overall, these results indicate that the RTS,S/AS02A vaccine has a good safety profile and well tolerated when given in three doses to semi-immune children living in malaria-endemic areas...
- Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of ResearchKent E Kester
Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
Vaccine 26:2191-202. 2008....
- Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02ADouglas S Walsh
Department of Immunology and Medicine, US Army Medical Component, Armed Forces Research Institute of Medical Sciences AFRIMS, Bangkok, Thailand
Vaccine 24:4167-78. 2006..In field studies, RTS,S/AS02A reduced malaria infection, clinical episodes, and disease severity. Heterologous prime-boost immunization regimens, optimally spaced, might improve the protective immunity of RTS,S/AS02A...
- Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trialPedro L Alonso
Centre de Salut Internacional, Hospital Clinic IDIBAPS, Universitat de Barcelona, Barcelona, Spain
Lancet 364:1411-20. 2004..RTS,S/AS02A is a pre-erythrocytic vaccine candidate based on Plasmodium falciparum circumsporozoite surface antigen. We aimed to assess vaccine efficacy, immunogenicity, and safety in young African children...
- Development of a recombinant FimCH vaccine for urinary tract infectionsSolomon Langermann
MedImmune, Inc, Gaithersburg, MD, USA
Adv Exp Med Biol 539:635-48. 2003
- Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeysDouglas S Walsh
Department of Immunology and Medicine, U S Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
Am J Trop Med Hyg 70:499-509. 2004..RTS,S+TRAP/AS02A was safe and well tolerated. Vigorous antibody production and modest, selective cell-mediated immune responses suggest that RTS,S+TRAP/AS02A may be immunogenic in human infants...
- Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccineEvelina Angov
Department of Immunology, WRAIR, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
Mol Biochem Parasitol 128:195-204. 2003..FMP1 formulated with GlaxoSmithKline Biologicals (GSK) adjuvant, AS02A or alum was safe and immunogenic in rhesus (Macaca mulatta) monkeys...
- Pre-erythrocytic malaria vaccines to prevent Plasmodium falciparum malariaW Ripley Ballou
MedImmune Inc, Gaithersburg, MD, USA
Chem Immunol 80:253-61. 2002
- Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malariaEdwin A M Lee
Molecular Immunology Group, Nuffield Department of Medicine, Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, United Kingdom
Infect Immun 70:1417-21. 2002..These data suggest that epitope-specific naturally acquired MSP-1(19) immune responses in endemic populations can be boosted by vaccination...
- Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trialHans C Rumke
Vaxinostics BV, University Vaccine Center Rotterdam Nijmegen, Beursplein 37, PO Box 30142, 3001 DC Rotterdam, The Netherlands
Vaccine 26:2378-88. 2008..The safety and reactogenicity profile of the AS-H5N1 candidate vaccine can be considered clinically acceptable in the context of its use against pandemic influenza...